← Eichor
Condition: Msi H Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Msi H Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Canc
Phase 1 · 1 location(s) · West China Hospital · NCT07076823ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770102PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsa
Phase 3 · 1 location(s) · Centre Hospitalier Universitaire Dijon · NCT06762405Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Phase 2 · 4 location(s) · Sun Yat-sen University · NCT03810339AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Phase 1 · 22 location(s) · Amgen · NCT07403721PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05236972Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03926338Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NA · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04643041Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06903858A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06686576Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
NA · 1 location(s) · Jessica Mezzanotte Sharpe · NCT07555210The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cance
Phase N/A · 1 location(s) · Yunnan Cancer Hospital · NCT06477991KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase 2 · 1 location(s) · 3D Medicines (Sichuan) Co., Ltd. · NCT03667170Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Me
Phase N/A · 20 location(s) · Federation Francophone de Cancerologie Digestive · NCT06353854Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Phase 1 · 1 location(s) · Allegheny Singer Research Institute (also known as Allegheny · NCT07001592Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Phase 2 · 9 location(s) · Royal Marsden NHS Foundation Trust · NCT06250036Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
EARLY_Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07128355Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT04636008A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Phase 1/Phase 2 · 22 location(s) · Nimbus Wadjet, Inc. · NCT06898450Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Phase 2 · 1 location(s) · University Medical Center Groningen · NCT05483400A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 an
Phase 2 · 39 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06948448A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNO
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT02332668Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 · 30 location(s) · BeiGene · NCT03736889Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or
Phase 2 · 5 location(s) · Emory University · NCT07140679KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06099821FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 33 location(s) · Parabilis Medicines, Inc. · NCT05919264Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Col
Phase N/A · 2 location(s) · Geneplus-Beijing Co. Ltd. · NCT06098560A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Phase 1 · 1 location(s) · Jemincare · NCT07208136
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.